Effects of halogenated inhalational agents on the liver and kidneys

Problems in Anesthesia

Volumn 10, Issue 4, 1998, Pages 478-487

  Njoku, Dolores B ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DESFLURANE; ENFLURANE; INHALATION ANESTHETIC AGENT; ISOFLURANE; METHOXYFLURANE; SEVOFLURANE;

ANESTHESIA INDUCTION; CHILD; DRUG EFFECT; DRUG SOLUBILITY; HUMAN; IMMUNOHISTOCHEMISTRY; INHALATION ANESTHESIA; KIDNEY FAILURE; LIVER CELL; LIVER TOXICITY; MINIMUM LUNG ALVEOLUS CONCENTRATION; NEPHROTOXICITY; PEDIATRIC ANESTHESIA; REVIEW; TOXIC HEPATITIS;

EID: 0032410852     PISSN: 08894698     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Johnston RR, Eger EI II, Wilson C. A comparative interaction of epinephrine with enflurane, isoflurane, and halothane in man. Anesth Analg 1976;55:709-712.
2. Wright R, Eade OE, Chisholm M, et al. Controlled prospective study of the effect on liver function of multiple exposures to halothane. Lancet 1975;1:817-820.
3. Moult PJ, Sherlock S. Halothane-related hepatitis. A clinical study of twenty-six cases. Q J Med 1975;44: 99-114.
4. Stoelting RK, Longshore RE. The effects of temperature on fluroxene, halothane, and methoxyflurane blood-gas and cerebrospinal fluid - gas partition coefficients. Anesthesiology 1972;36:503-505.
5. Crandell WB, Pappas SG, Macdonald A. Nephrotoxicity associated with methoxyflurane anesthesia. Anesthesiology 1966;27:591-607.
6. Mazze RI, Trudell JR, Cousins MJ. Methoxyflurane metabolism and renal dysfunction: clinical correlation in man. Anesthesiology 1971;35:247-252.
7. Cousins MJ, Mazze RI. Methoxyflurane nephrotoxicity. A study of dose response in man. JAMA 1973;225: 1611-1616.
8. Cousins MJ, Greenstein LR, Hitt BA, Mazze RI. Metabolism and renal effects of enflurane in man. Anesthesiology 1976;44:44-53.
9. Mazze RI, Sievenpiper TS, Stevenson J. Renal effects of enflurane and halothane in patients with abnormal renal function. Anesthesiology 1984;60:161-163.
10. Carrigan TW, Straughen WJ. A report of hepatic necrosis and death following isoflurane anesthesia. Anesthesiology 1987;67:581-583.
11. Jones RM. Desflurane and sevoflurane: inhalation anaesthetics for this decade? Br J Anaesth 1990;65: 527-536.
12. Martin JL, Plevak DJ, Flannery KD, et al. Hepatotoxicity after desflurane anesthesia. Anesthesiology 1995; 83:1125-1129.
13. Targ AG, Yasuda N, Eger EI 2d. Solubility of 1-653, sevoflurane, isoflurane, and halothane in plastics and rubber composing a conventional anesthetic circuit. Anesth Analg 1989;69:218-225.
14. Shiraishi Y, Ikeda K. Uptake and biotransformation of sevoflurane in humans: a comparative study of sevoflurane with halothane, enflurane, and isoflurane. J Clin Anesth 1990;2:381-386.
15. Epstein RM, Deutsch S, Cooperman LH, Clement AJ, Price HL. Splanchnic circulation during halothane anesthesia and hypercapnia in normal man. Anesthesiology 1966;27:654-661.
16. Stevens WC, Cromwell TH, Halsey MJ, Eger EI II, Shakespeare TF, Bahlman SH. The cardiovascular effects of a new inhalation anesthetic, Forane, in human volunteers at constant arterial carbon dioxide tension. Anesthesiology 1971;35:8-16.
17. Gelman S, Fowler KC, Smith LR. Regional blood flow during isoflurane and halothane anesthesia. Anesth Analg 1984;63:557-565.
18. Gelman S, Fowler KC, Smith LR. Liver circulation and function during isoflurane and halothane anesthesia. Anesthesiology 1984;61:726-730.
19. Lundeen G, Manohar M, Parks C. Systemic distribution of blood flow in swine while awake and during 1.0 and 1.5 MAC isoflurane anesthesia with or without 50% nitrous oxide. Anesth Analg 1983;62:499-512.
20. Bernard JM, Doursout MF, Wouters P, et al. Effects of enflurane and isoflurane on hepatic and renal circulations in chronically instrumented dogs. Anesthesiology 1991;74:298-302.
21. Merin RG, Bernard JM, Doursout MF, Cohen M, Chelly JE. Comparison of the effects of isoflurane and desflurane on cardiovascular dynamics and regional blood flow in the chronically instrumented dog. Anesthesiology 1991;74:568-574.
22. Reilly CS, Wood AJ, Koshakji RP, Wood M. The effect of halothane on drug disposition: contribution of changes in intrinsic drug metabolizing capacity and hepatic blood flow. Anesthesiology 1985;63:70-76.
23. Carney FM, Van Dyke RA. Halothane hepatitis: a critical review. Anesth Analg 1972;51:135-160.
24. Lewis JH, Zimmerman HJ, Ishak KG, Mullick FG. Enflurane hepatotoxicity. A clinicopathologic study of 24 cases. Ann Intern Med 1983;98:984-992.
25. Eger EI II, Smuckler EA, Ferrell LD, Goldsmith CH, Johnson BH. Is enflurane hepatotoxic? Anesth Analg 1986;65:21-30.
26. Warner LO, Beach TP, Garvin JP, Warner EJ. Halothane and children: the first quarter century. Anesth Analg 1984;63:838-840.
27. Kenna JG, Satoh H, Christ DD, Pohl LR. Metabolic basis for a drug hypersensitivity: antibodies in sera from patients with halothane hepatitis recognize liver neoantigens that contain the trifluoroacetyl group derived from halothane. J Pharmacol Exp Ther 1988;245:1103-1109.
28. Neuberger J, Mieli-Vergani G, Tredger JM, Davis M, Williams R. Oxidative metabolism of halothane in the production of altered hepatocyte membrane antigens in acute halothane-induced hepatic necrosis. Gut 1981;22:669-672.
29. Pohl LR, Thomassen D, Pumford NR, et al. Hapten carrier conjugates associated with halothane hepatitis. Adv Exp Med Biol 1991;283:111-120.
30. Pohl LR. An immunochemical approach of identifying and characterizing protein targets of toxic reactive metabolites. Chem Res Toxicol 1993;6:786-793.
31. Njoku D, Laster MJ, Gong DH, Eger EIII, Reed GF, Martin JL. Biotransformation of halothane, enflurane, isoflurane, and desflurane to trifluoroacetylated liver proteins: association between protein acylation and hepatic injury. Anesth Analg 1997;84:173-178.
32. Holaday DA, Fiserova-Bergerova V, Latto IP, Zumbiel MA. Resistance of isoflurane to biotransformation in man. Anesthesiology 1975;43:325-332.
33. Cohen EN, Trudell JR, Edmunds HN, Watson E. Urinary metabolites of halothane in man. Anesthesiology 1975;43:392-401.
34. Gut J, Christen U, Huwyler J. Mechanisms of halothane toxicity: novel insights. Pharmacol Ther 1993;58: 133-155.
35. Kenna JG, Neuberger J, Mieli-Vergani G, Mowat AP, Williams R. Halothane hepatitis in children. Br Med J 1987;294:1209-1211.
36. Martin JL, Dubbink DA, Plevak DJ, et al. Halothane hepatitis 28 years after primary exposure. Anesth Analg 1992;74:605-608.
37. Ni J, Sato N, Fujii K, Yuge O. Urinary excretion of hexafluoroisopropanol glucuronide and fluoride in patients after sevoflurane anaesthesia. J Pharm Pharmacol 1993; 45:67-69.
38. Crank G, Harding DR, Szinai SS. Perfluoroalkyl carbonyl compounds. 2. Derivatives of hexafluoroacetone. J Med Chem 1970;13:1215-1217.
39. Kharasch ED, Karol MD, Lanni C, Sawchuk R. Clinical sevoflurane metabolism and disposition. I. Sevoflurane and metabolite pharmacokinetics. Anesthesiology 1995; 82:1369-1378.
40. Payne AK, Morgan SE, Gandolfi AJ, Brendel K. Biotransformation of sevoflurane by rat neonate liver slices. Drug Metab Dispos 1995;23:497-500.
41. Martis L, Lynch S, Napoli MD, Woods EF. Biotransformation of sevoflurane in dogs and rats. Anesth Analg 1981;60:186-191.
42. Watkins JB, Klaassen CD. Development of UDP-glucuronosyltransferase activity toward digitoxigenin-monodigitoxoside in neonatal rats. Drug Metab Dispos 1985; 13:186-191.
43. Frink EJ Jr, Green WB Jr, Brown EA, et al. Compound A concentrations during sevoflurane anesthesia in children. Anesthesiohgy 1996;84:566-571.
44. Whitford GM, Taves DR. Fluoride-induced diuresis: renal-tissue solute concentrations, functional, hemodynamic, and histologiccorrelates in the rat. Anesthesiology 1973;39:416-427.
45. Carpenter RL, Eger EI II, Johnson BH, Unadkat JD, Sheiner LB. The extent of metabolism of inhaled anesthetics in humans. Anesthesiology 1986;65:201-205.
46. White AE, Stevens WC, Eger EI II, Mazze RI, Hitt BA. Enflurane and methoxyflurane metabolism at anesthetic and at subanesthetic concentrations. Anesth Analg 1979;58:221-224.
47. Kharasch ED, Hankins DC, Thummel KE. Human kidney methoxyflurane and sevoflurane metabolism. Intrarenal fluoride production as a possible mechanism of methoxyflurane nephrotoxicity. Anesthesiology 1995; 82:689-699.
48. Frink EJ Jr, Ghantous H, Malan TP, et al. Plasma inorganic fluoride with sevoflurane anesthesia: correlation with indices of hepatic and renal function. Anesth Analg 1992;74:231-235.
49. Higuchi H, Sumikura H, Sumita S, et al. Renal function in patients with high serum fluoride concentrations after prolonged sevoflurane anesthesia. Anesthesiology 1995;83:449-458.
50. Goldberg ME, Cantillo J, Larijani GE, Torjman M, Vekeman D, Schieren H. Sevoflurane versus isoflurane for maintenance of anesthesia: are serum inorganic fluoride ion concentrations of concern? Anesth Analg 1996;82:1268-1272.
51. Mono M, Fujii K, Satoh N, et al. Reaction of sevoflurane and its degradation products with soda lime. Toxicity of the byproducts. Anesthesiology 1992;77:1155-1164.
52. Gonsowski CT, Laster MJ, Eger EI II, Ferrell LD, Kerschmann RL. Toxicity of compound A in rats. Effect of a 3-hour administration. Anesthesiohgy 1994;80:556-565.
53. Keller KA, Callan C, Prokocimer P, et al. Inhalation toxicity study of a haloalkene degradant of sevoflurane, Compound A (PIFE), in Sprague-Dawley rats. Anesthesiology 1995;83:1220-1232.
54. Martin JL, Laster MJ, Kandel L, Kerschmann RL, Reed GF, Eger EI II. Metabolism of compound A by renal cysteine-S-conjugate beta-lyase is not the mechanism of compound A-induced renal injury in the rat. Anesth Analg 1996;82:770-774.
55. Eger EI II, Ionescu P, Koblin DD, Weiskopf RB. Compound A: solubility in saline and olive oil; destruction by blood. Anesth Analg 1996;83:849-853.
56. 3) (compound A): the safety of halothane does not indicate the safety of sevoflurane. Anesth Analg 1997;85:1164-1170.
57. 2 absorbants during low-flow anesthesia in surgical patients. Anesthesiology 1992;77:1064-1069.
58. Bito H, Ikeda K. Long-duration, low-flow sevoflurane anesthesia using two carbon dioxide absorbents. Quantification of degradation products in the circuit. Anesthesiology 1994;81:340-345.
59. Eger EI II, Koblin DD, Bowland T, et al. Nephrotoxicity of sevoflurane versus desflurane anesthesia in volunteers. Anesth Analg 1997;84:160-168.
60. Eben TJ, Frink EJ Jr, Kharasch ED. Absence of biochemical evidence for renal and hepatic dysfunction after 8 hours of 1.25 minimum alveolar concentration sevoflurane anesthesia in volunteers. Anesthesiology 1998;88:601-610.
61. Kharasch ED, Frink EJ Jr, Zager R, Bowdle TA, Artru A, Nogami WM. Assessment of low-flow sevoflurane and isoflurane effects on renal function using sensitive markers of tubular toxicity. Anesthesiology 1997;86: 1238-1253.
62. Bito H, Ikeuchi Y, Ikeda K. Effects of low-flow sevoflurane anesthesia on renal function: comparison with high-flow sevoflurane anesthesia and low-flow isoflurane anesthesia. Anesthesiology 1997;86:1231-1237.